Compare · DXCM vs STIM
DXCM vs STIM
Side-by-side comparison of DexCom Inc. (DXCM) and Neuronetics Inc. (STIM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and STIM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 262.4x STIM ($112.7M).
- Over the past year, DXCM is down 8.8% and STIM is down 58.2% - DXCM leads by 49.5 points.
- DXCM has been more active in the news (4 items in the past 4 weeks vs 3 for STIM).
- DXCM has more recent analyst coverage (25 ratings vs 4 for STIM).
- Company
- DexCom Inc.
- Neuronetics Inc.
- Price
- $76.65-1.74%
- $1.62-9.24%
- Market cap
- $29.58B
- $112.7M
- 1M return
- +4.76%
- +33.33%
- 1Y return
- -8.79%
- -58.25%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2018
- News (4w)
- 4
- 3
- Recent ratings
- 25
- 4
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Neuronetics Inc.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest STIM
- Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)
- New insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)
- Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
- SEC Form 8-K filed by Neuronetics Inc.
- Director Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)
- Large owner Madryn Asset Management, Lp acquired 72,500 shares (SEC Form 4)
- Neuronetics Appoints Robert Greene as Senior Vice President Sales
- SEC Form SD filed by Neuronetics Inc.
- Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)
- Director Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)